These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7865386)

  • 1. Treatment of systemic sclerosis.
    van den Hoogen FH; van de Putte LB
    Curr Opin Rheumatol; 1994 Nov; 6(6):637-41. PubMed ID: 7865386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of systemic sclerosis.
    Pope J
    Curr Opin Rheumatol; 1993 Nov; 5(6):792-801. PubMed ID: 7509616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapeutic strategies for systemic sclerosis--a critical analysis of the literature.
    Zandman-Goddard G; Tweezer-Zaks N; Shoenfeld Y
    Clin Dev Immunol; 2005 Sep; 12(3):165-73. PubMed ID: 16295521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
    Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of systemic sclerosis.
    Steen V
    Curr Opin Rheumatol; 1991 Dec; 3(6):979-85. PubMed ID: 1722990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
    Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
    Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis.
    Knobler RM; French LE; Kim Y; Bisaccia E; Graninger W; Nahavandi H; Strobl FJ; Keystone E; Mehlmauer M; Rook AH; Braverman I;
    J Am Acad Dermatol; 2006 May; 54(5):793-9. PubMed ID: 16635659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.
    Meyrick Thomas RH; Rademaker M; Grimes SM; MacKay A; Kovacs IB; Cook ED; Bowcock SM; Kirby JD
    Br J Dermatol; 1987 Aug; 117(2):237-41. PubMed ID: 3307894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracorporeal photochemotherapy in progressive systemic sclerosis: a follow-up study.
    Schwartz J; Gonzalez J; Palangio M; Klainer AS; Bisaccia E
    Int J Dermatol; 1997 May; 36(5):380-5. PubMed ID: 9199991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma.
    Engelhart M
    Br J Dermatol; 1988 Dec; 119(6):751-4. PubMed ID: 3060193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
    Kahan A; Amor B; Menkes CJ
    Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Systemic sclerosis].
    Tamborrini G; Distler M; Distler O
    Med Monatsschr Pharm; 2008 May; 31(5):162-70; quiz 171-2. PubMed ID: 18552072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug treatment of scleroderma.
    Leighton C
    Drugs; 2001; 61(3):419-27. PubMed ID: 11293650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of patients with systemic sclerosis].
    Wiesik-Szewczyk E; Olesińska M
    Pol Merkur Lekarski; 2010 May; 28(167):421-3. PubMed ID: 20568411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
    Henness S; Wigley FM
    Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.